Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM


Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM
Slides from presentations at ASCO 2011 and comments from Sergio Giralt, MD

Dimopoulos MA et al. Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. Proc ASCO 2011;Abstract 8009.

Dr Giralt is Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan-Kettering Cancer Center in New York, New York.